New data find reduced bleeding risk for DOACs in extended VTE prophylaxis
Recent studies have shown that oral anticoagulants can decrease VTE risk when used for extended prophylaxis, but physicians have worried—rightly so—that the bleeding risks outweighed the benefits of anticoagulation. But new data found that by excluding patients at high risks of bleeding, one DOAC was able to significantly reduce VTE events in patients after discharge. Read more about the study and the potential impact the data will likely have on hospitalists. Read more.
Reducing VTE risk in post-discharge patients with extended prophylaxis
While studies show that medically ill patients face a heightened risk of VTE events after discharge, data show that fewer than 5% of those patients receive any kind of extended thromboprophylaxis post-discharge. Just how serious is the risk of VTE to patients post-discharge, and who are the likely candidates for extended prophylaxis? We talk to two physicians about the risks of VTE in the post-discharge population. Read more.
How issues with heparin are affecting VTE prophylaxis in the hospital
kali9
When it comes to VTE prophylaxis, the traditional therapy—heparin or LMWH—presents physicians with some challenges. From a looming worldwide shortage of heparin to compliance problems with patients who would rather not get needles all the time, we take a look at some of the issues surrounding a mainstay of anticoagulation. Read more.
